Kura Oncology (NASDAQ:KURA) Sees Unusually-High Trading Volume – Time to Buy?

Kura Oncology, Inc. (NASDAQ:KURA) saw strong trading volume on Thursday . 1,924,539 shares changed hands during mid-day trading, an increase of 31% from the previous session’s volume of 1,472,741 shares.The stock last traded at $11.0290 and had previously closed at $10.34.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. Wall Street Zen upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Saturday, May 16th. Wedbush dropped their target price on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating for the company in a report on Friday, March 6th. UBS Group restated a “buy” rating and issued a $15.00 target price (down from $16.00) on shares of Kura Oncology in a report on Friday, March 13th. Finally, Lake Street Capital began coverage on Kura Oncology in a report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 target price for the company. Ten equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $26.38.

Kura Oncology Trading Up 1.1%

The company has a 50 day moving average price of $9.01 and a 200 day moving average price of $9.45. The firm has a market cap of $998.66 million, a price-to-earnings ratio of -3.36 and a beta of 0.32. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.14 and a current ratio of 6.15.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 141.95% and a negative net margin of 411.19%.The business had revenue of $18.27 million for the quarter, compared to analyst estimates of $25.97 million. On average, research analysts expect that Kura Oncology, Inc. will post -3.23 earnings per share for the current year.

Hedge Funds Weigh In On Kura Oncology

Large investors have recently modified their holdings of the business. Sector Gamma AS acquired a new position in Kura Oncology during the 3rd quarter worth about $3,880,000. Nan Fung Trinity HK Ltd. acquired a new position in Kura Oncology during the 3rd quarter worth about $2,043,000. SG Americas Securities LLC lifted its stake in Kura Oncology by 214.1% during the 4th quarter. SG Americas Securities LLC now owns 151,715 shares of the company’s stock worth $1,576,000 after acquiring an additional 103,411 shares in the last quarter. UBS Group AG lifted its stake in Kura Oncology by 118.3% during the 4th quarter. UBS Group AG now owns 1,060,025 shares of the company’s stock worth $11,014,000 after acquiring an additional 574,455 shares in the last quarter. Finally, Rhenman & Partners Asset Management AB lifted its stake in Kura Oncology by 96.0% during the 3rd quarter. Rhenman & Partners Asset Management AB now owns 490,000 shares of the company’s stock worth $4,336,000 after acquiring an additional 240,000 shares in the last quarter.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.